Mangoceuticals (MGRX) Retained Earnings (2022 - 2026)

Mangoceuticals (MGRX) has 5 years of Retained Earnings data on file, last reported at -$44.1 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 1983269.2% year-over-year to -$44.1 million; the trailing twelve-month figure through Mar 2026 stood at -$44.1 million (down 1983269.2% YoY), and the FY2025 full-year result was -$40.6 million, down 216.85% from the prior year.
• Retained Earnings declined to -$44.1 million in Q1 2026, from -$40.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $34.8 million in Q4 2024 to a low of -$44.1 million in Q1 2026.
• A 5-year average of -$7.0 million and a median of -$7.8 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 541.65% in 2024 and slumped 1983269.2% in 2026, its largest moves.
• Tracing MGRX's Retained Earnings over 5 years: stood at $2.6 million in 2022, then slumped by 527.18% to -$11.2 million in 2023, then soared by 409.81% to $34.8 million in 2024, then tumbled by 216.85% to -$40.6 million in 2025, then declined by 8.37% to -$44.1 million in 2026.
• Business Quant data shows MGRX's Retained Earnings at -$44.1 million in Q1 2026, -$40.6 million in Q4 2025, and -$2079.0 in Q3 2025.